The Jonsson Comprehensive Cancer Center (JCCC) is a cancer research center at University of California, Los Angeles.
The center was originated by UCLA scientists and volunteers who began working together in the late 1960s.[1] The center was formally established in 1974 and was designated as a comprehensive cancer center by the National Cancer Institute in 1976.[1] [2] The namesake of the center is the Jonsson family; entrepreneur and philanthropist Kenneth Alan Jonsson (the son of Texas Instruments co-founder J. Erik Jonsson), along with his wife Diana Gordon Jonsson, made a $1 million gift for UCLA in 1975 to establish the center, and continued to financially support the center over a period of decades.[3] [4]
Joseph W. Cullen served as a deputy director of the center.[5]
The primary sponsor of the center is the Jonsson Cancer Center Foundation (JCCF),[2] a 501(c)(3) entity (established in 1945).[6]
The center employs over 500 physicians and scientists, who engage in clinical activities (i.e., cancer treatment), education, research (basic and clinical), and cancer prevention.[1] [2] [7]
Although based at UCLA, the center has clinics elsewhere in California, in Westwood, Santa Monica, Alhambra, Irvine, Pasadena, Porter Ranch, Santa Clarita, and Simi Valley.[2]
The center is known for its research on breast and ovarian cancer.[2] JCCC scientists developed palbociclib (PD 0332991), a breast-cancer drug that was in phase III clinical trials as of 2015.[2] JCCC scientists also identified IGF-1 as a pathway as one pathway for the growth of tumors.[2]
In 2013, U.S. News & World Report ranked JCCC as #11 nationally among cancer centers.[2] In 2015, the center ranked #6.[8]
In 2023, U.S. News & World Report ranked JCCC #4 nationally and #1 in California among cancer centers. [9]